Popular Stories

Atopic Dermatitis Tag

  • All
  • Biotechnology
  • Cannabis
  • Education
  • Energy
  • Investing Ideas
  • Macro
  • Miscellaneous
  • Sectors
  • Startups
  • Technologies
  • Trending
  • Uncategorized
On the Verge of commercialization with Odevixibat!

Albireo Pharma, Inc. (NASDAQ: ALBO) a clinical-stage company targeting rare liver diseases, announced the acceptance of its New Drug Application (NDA) for odevixibat, a once-daily, non-systemic IBAT, intended for the treatment of pruritus in patients with progressive familial intrahepatic cholestasis (PFIC). The candidate is also...

Emerging treatment approaches in Pruritus

Pruritus is characterized by an uncomfortable and persistent urge to scratch caused either due to a skin disorder or an underlying systemic disease such as atopic dermatitis, mycoses, chickenpox, hepatitis, Jaundice, chronic renal failure, cholestasis or NASH. These can be chronic in nature and affect...

WordPress Video Lightbox Plugin